| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a431cf4c64da0f89eccaa9aa30b43b7f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 |
| filingDate |
2020-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0fdeca465dd08ee6025bc905ee91a5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deb68b18c4194a57d89a538496ce4294
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abafac4549c410b3bde78daf381f4ae0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6d4c3930d91cacd4dc233ef2d709ac8 |
| publicationDate |
2020-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111803511-A |
| titleOfInvention |
DNA tetrahedral nucleic acid framework type gastric cancer diagnosis and treatment integrated reagent and preparation method and application thereof |
| abstract |
The invention discloses a DNA tetrahedral nucleic acid framework type gastric cancer diagnosis and treatment integrated reagent, which comprises a DNA tetrahedral nucleic acid framework and is loaded with chemotherapeutic drugs, and is obtained by connecting a MUC1 targeting aptamer and Mcl-1 siRNA. The invention also discloses the preparation method and application of the integrated reagent. The integrated reagent provided by the present invention can identify drug-resistant gastric cancer cells SGC-7901/ADR by targeting, miRNA detection and imaging, and synergistically treat chemical drugs and gene silencing, thereby improving the internalization efficiency of the reagent in drug-resistant gastric cancer cells and the The efficiency of miRNA detection and the structural changes of the nucleic acid framework during the miRNA detection process are used to realize the rapid release of DOX loaded in DNA double strands. The reagent also combines Mcl-1 siRNA, and the gene silencing of Mcl-1 siRNA significantly improves the therapeutic effect of DOX and overcomes the drug resistance problem in the application of nano-drugs in biological systems. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112251488-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112251488-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114099695-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113736776-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114306625-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115025045-A |
| priorityDate |
2020-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |